ArticleTherapeutic advances in medical oncology2024

Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.

Van Luan Pham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.